613 reports of this reaction
1.5% of all LURASIDONE HYDROCHLORIDE reports
#17 most reported adverse reaction
SEDATION is the #17 most commonly reported adverse reaction for LURASIDONE HYDROCHLORIDE, manufactured by Sumitomo Pharma America, Inc.. There are 613 FDA adverse event reports linking LURASIDONE HYDROCHLORIDE to SEDATION. This represents approximately 1.5% of all 41,710 adverse event reports for this drug.
Patients taking LURASIDONE HYDROCHLORIDE who experience sedation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEDATION is a less commonly reported adverse event for LURASIDONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to sedation, the following adverse reactions have been reported for LURASIDONE HYDROCHLORIDE:
The following drugs have also been linked to sedation in FDA adverse event reports:
SEDATION has been reported as an adverse event in 613 FDA reports for LURASIDONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEDATION accounts for approximately 1.5% of all adverse event reports for LURASIDONE HYDROCHLORIDE, making it a notable side effect.
If you experience sedation while taking LURASIDONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.